254 related articles for article (PubMed ID: 21677600)
21. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia.
Pethig K; Heublein B; Wahlers T; Dannenberg O; Oppelt P; Haverich A
J Heart Lung Transplant; 2004 Jan; 23(1):61-6. PubMed ID: 14734128
[TBL] [Abstract][Full Text] [Related]
22. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.
Bergh N; Gude E; Bartfay SE; K Andreassen A; Arora S; Dahlberg P; Dellgren G; Gullestad L; Gustafsson F; Karason K; Rådegran G; Bollano E; Andersson B
ESC Heart Fail; 2020 Apr; 7(2):567-576. PubMed ID: 32059083
[TBL] [Abstract][Full Text] [Related]
23. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
25. Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy.
Sánchez-Brotons JA; Sobrino-Márquez JM; Lage-Gallé E; Romero-Rodriguez N; Guisado A; Jiménez-Díaz J; Benezet-Mazuecos J; Arizón-Muñoz JM; Mogollón MV; Martínez A
Transplant Proc; 2008 Nov; 40(9):3046-8. PubMed ID: 19010188
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
Annemans L; Lemkuhl H; Tenderich G; Schulz U; Yang XL; Ricci JF; Hetzer R
Transplant Proc; 2007 Dec; 39(10):3306-12. PubMed ID: 18089377
[TBL] [Abstract][Full Text] [Related]
27. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
28. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
Kobashigawa J; Ross H; Bara C; Delgado JF; Dengler T; Lehmkuhl HB; Wang SS; Dong G; Witte S; Junge G; Potena L
Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
[TBL] [Abstract][Full Text] [Related]
29. Vascular remodeling 1 year after cardiac transplantation.
Li H; Tanaka K; Chhabra A; Oeser B; Kobashigawa JA; Tobis JM
J Heart Lung Transplant; 2007 Jan; 26(1):56-62. PubMed ID: 17234518
[TBL] [Abstract][Full Text] [Related]
30. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
[TBL] [Abstract][Full Text] [Related]
31. Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation.
Dandel M; Jasaityte R; Lehmkuhl H; Knosalla C; Hetzer R
Transplant Proc; 2009; 41(6):2585-8. PubMed ID: 19715979
[TBL] [Abstract][Full Text] [Related]
32. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
[TBL] [Abstract][Full Text] [Related]
33. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
[TBL] [Abstract][Full Text] [Related]
34. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
Vítko S; Margreiter R; Weimar W; Dantal J; Viljoen HG; Li Y; Jappe A; Cretin N;
Transplantation; 2004 Nov; 78(10):1532-40. PubMed ID: 15599319
[TBL] [Abstract][Full Text] [Related]
35. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
36. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
Zuckermann A; Wang SS; Epailly E; Barten MJ; Sigurdardottir V; Segovia J; Varnous S; Turazza FM; Potena L; Lehmkuhl HB
Transplant Rev (Orlando); 2013 Jul; 27(3):76-84. PubMed ID: 23643624
[TBL] [Abstract][Full Text] [Related]
37. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.
Eisen HJ; Kobashigawa J; Keogh A; Bourge R; Renlund D; Mentzer R; Alderman E; Valantine H; Dureau G; Mancini D; Mamelok R; Gordon R; Wang W; Mehra M; Constanzo MR; Hummel M; Johnson J;
J Heart Lung Transplant; 2005 May; 24(5):517-25. PubMed ID: 15896747
[TBL] [Abstract][Full Text] [Related]
38. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
Potena L; Fearon WF; Sydow K; Holweg C; Luikart H; Chin C; Weisshaar D; Mocarski ES; Lewis DB; Valantine HA; Cooke JP
Transplantation; 2008 Mar; 85(6):827-33. PubMed ID: 18360263
[TBL] [Abstract][Full Text] [Related]
39. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R
J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
[TBL] [Abstract][Full Text] [Related]
40. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
